Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for progressive or recurrent glioblastoma
ChiCTR-OPC-17013350Phase 4Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Dec 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in glioblastoma (GBM), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: 6-month progression-free survival rate and 6-month objective response rate. Started Dec 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR-OPC-17013350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17013350.